Global Vaccine Partnering Deals Report/Directory 2021: Deal Trends, Players and Financials 2021-2021

News provided by

Sep 10, 2021, 09:00 ET

DUBLIN, Sept. 10, 2021 /PRNewswire/ -- Gain comprehensive access to over 900 vaccine deal records from this report "Global Vaccine Partnering Terms and Agreements 2014-2020: Deal Trends, Players and Financials" that has been added to ResearchAndMarkets.com's offering.

The Global Vaccine Partnering Terms and Agreements 2014-2021: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in vaccine and adjuvant partnering deals
Deal terms analysis
Partnering agreement structure
Partnering contract documents
Top deals by value
Most active dealmakers
Average deal terms for vaccines

This report contains a comprehensive listing of all vaccine partnering deals announced since January 2014, including financial terms where available, including over 900 links to online deal records of actual vaccine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The report takes readers through the vaccine deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering vaccine partnering deals.

The report presents average financial deal terms values for vaccine deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The middle section of the report explores the leaders in the vaccine partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made.

One of the key highlights of the report is that over 900 online deals records of actual vaccine deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Finally the report concludes by looking into the future of vaccine partnering. With so many innovators looking for the next big thing in the field, the report selects companies to watch who are predicted to become big in the field based on their current dealmaking and financial trends.

Throughout the report various tables, figures and graphs are embedded in order to illustrate the trends and partnering activities of the vaccine field.

By the end of the report prospective dealmakers will have gained a thorough understanding of the partnering landscape of the vaccine market and will be familiar with the values and structures of the deals being signed within it.

Global Vaccine Partnering Terms and Agreements 2014-2021: Deal trends, players and financials is intended to provide the reader with an in-depth understanding and access to vaccine trends and structure of deals entered into by leading companies worldwide.

Global Vaccine Partnering Terms and Agreements 2014-2021: Deal trends, players and financials includes:

Trends in vaccine dealmaking in the biopharma industry since 2014
Analysis of vaccine deal structure
Access to headline, upfront, milestone and royalty data
Access to over 900 vaccine deal documents
The leading vaccine deals by value since 2014
Most active vaccine dealmakers since 2014
The leading vaccine partnering resources

In Global Vaccine Partnering Terms and Agreements 2014-2021: Deal trends, players and financials, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Therapy target
Specific technology type

Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Vaccine Partnering Terms and Agreements 2014-2021: Deal trends, players and financials report provides comprehensive access to available deals and contract documents for over 900 vaccine deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise vaccine rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Vaccines dealmaking
2.1. Introduction
2.2. Vaccines partnering over the years
2.3. Most active Vaccines dealmakers
2.4. Vaccines partnering by deal type
2.5. Vaccines partnering by therapy area
2.6. Deal terms for Vaccines partnering
2.6.1 Vaccines partnering headline values
2.6.2 Vaccines deal upfront payments
2.6.3 Vaccines deal milestone payments
2.6.4 Vaccines royalty rates

Chapter 3 - Leading Vaccines deals
3.1. Introduction
3.2. Top Vaccines deals by value

Chapter 4 - Most active Vaccines dealmakers
4.1. Introduction
4.2. Most active Vaccines dealmakers
4.3. Most active Vaccines partnering company profiles

Chapter 5 - Vaccines contracts dealmaking directory
5.1. Introduction
5.2. Vaccines contracts dealmaking directory

Chapter 6 - Vaccines dealmaking by technology type

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Companies Mentioned

2A
3SBio
A*STAR' Institute of Molecular and Cell Biology
ABIVAX
Accelovance
AC Immune
Advanced Biological Laboratories
Advanced BioNutrition
Advanced BioScience Laboratories
Advaxis
Aelix Therapeutics
Aeras
AEterna Zentaris
Aethlon Medical
Affinivax
AFFiRiS
Agenus Bio
Agilvax
Aldevron
Alliance for Biosecurity
Amaran Biotechnology
Amarna Therapeutics
American Dental Association
American Gene Technologies
AMR
Amyris
Analytical Bio-Chemistry Laboratories
AnGes MG
Anixa Biosciences
Annias Immunotherapeutics
Antigen Discovery
Antigen Express
Antitope
Apceth
Appili Therapeutics
Aptimmune Biologics
Araclon Biotech
Arcturus Therapeutics
Ariad Pharmaceuticals
Aridis Pharmaceuticals
Ark Animal Health
Artes Biotechnology
Asahi Kasei
Astellas Pharma
Asterias Biotherapeutics
AstraZeneca
Atreca
Avanzcare
AV Therapeutics
Batavia Biosciences
Batu Biologics
Bavarian Nordic
Baxter International
Bayer
Baylor College
Baylor College of Medicine
Baylor Institute for Immunology Research
Bellicum Pharmaceuticals
BGI
Bill and Melinda Gates Foundation
BioClones
bioCSL
Biofactura
Bio Farma
Biogen
Bioject Medical Technologies
Biokinetic Europe
BioLife Solutions
biologistex CCM
Biomedical Advanced Research and Development Authority
BiondVax
BioNTech
Biooutsource
BioSun Pharmed
BioTechnique
Biothera
BioVaxys
BioVest
Bluebird Bio
Blue Water Vaccines
Boehringer Ingelheim
Boehringer Ingelheim Vetmedica
Bonnie J. Addario Lung Cancer Foundation
Bpifrance
BravoVax
Brighton Biotech
Bristol-Myers Squibb
Broad Institute
Burnet Institute
Butantan Institute
Button Capital
Caliber Biotherapeutics
California Institute for Medical Researc
California Institute of Technology
Calimmune
Calixar
Cancer Research Technology
Cancer Research UK
CARB-X
Catalan Institute of Nanotechnology (ICN)
Celldex Therapeutics
Cellular Biomedicine
Cel Sci
Center for Biomarker Research in Medicine
Center for Genetic Engineering and Biotechnology (Cuba)
Centers for Disease Control and Prevention
Centogene
Centre Hospital University - Bordeaux
Ceva Sante Animale
Cevec Pharmaceuticals
Changchun BCHT Biotechnology
Children's Hospital Boston
China Animal Husbandry Industry
China National Biotech Group (CNBG)
Cilian
CiMaas
CiToxLAB
City of Hope
City of Hope Comprehensive Cancer Center
ClearPath
Cleveland Clinic
Clinigen
CMC Biologics
Coalition for Epidemic Preparedness Innovations
Cofactor Genomics
Columbia University
ContraFect
Corgenix Medical
Create Vaccine Company
Cristal Therapeutics
Crozet BioPharma
Crucell
CryoPort
Crystal Bioscience
CSL
CureVac
CYTLIMIC
Cytovant Sciences
d3 Medicine
Daiichi Sankyo
Dana-Farber Cancer Institute
DanDrit Biotech
Davospharma
DCPrime
Defense Advanced Research Projects Agency
Defense Threat Reduction Agency
Department of Defense
Department of Economic development of Montgomery County
Department of Health and Human Services
Diamyd Medical
Diavax Biosciences
Diaxonhit
DNAtrix
Duke University
Dyadic International
DynPort Vaccine Company
Eddingpharm
Elanco
Eli Lilly
EMD Serono
Emergent BioSolutions
Emergex Vaccines
Emmes
Emory University
Endo International
Enesi Pharma
Engility
EpiThany
Epivax
eTheRNA immunotherapies
Etna Biotech
Etubics
European Union
European Vaccine Initiative
Evaxion Biotech
Evvivax
Excivion
Exiqon
Federal Ministry of Education and Research (BMBF)
Fina Biosolutions
Finlay Institute
Flextronics
Flow Pharma

For more information about this report visit https://www.researchandmarkets.com/r/qhau9j

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets